
Scientists have identified that the main infection site of the COVID19 is in the lungs, and that the transmission route is airborne. Scientists have also confirmed that the amount of viral load correlates directly with the rate of disease transmission.
Research shows that vaccines can effectively control the epidemic. One of the basic principles in the vaccines that are currently approved is that they provide neutralizing antibodies against the Sars-COV-2 S protein. This means that they can inhibit the virus from binding with ACE2 receptors on a cells surface.
Professor Chen Zhiwei of the Department of Microbiology at the University of Hong Kong School of Medicine and director of the Institute of AIDS, published research results in the “Cell Host & Microbe” journal. The five main take-outs were as follows:
Although neutralizing antibodies can inhibit the infection of the virus in the lungs and reduce lung damage, it cannot effectively inhibit the infection of the virus in the upper respiratory tract.
People who receive the vaccine cannot be completely immune to the virus and they also have the ability to transmit the virus after they have been infected.
The immune population can also be infected, and it is likely to be highly contagious after infection
Regardless of whether you have been vaccinated or not, you should actively wear a mask in public and use qualified antiviral oral sprays. Only in this way can you further reduce your own infection and the possibility of infecting others.
In clinical treatment, neutralizing antibodies are helpless against virus infection in the turbinate

The COVID19 pandemic has so far claimed the lives of more than two million people. With the distribution of vaccines, the number of vaccine injections in some countries has already exceeded tens of millions and it seems that herd immunity is in sight. Some countries have even begun to consider issuing "immunization passports" from an economic point of view.
As Antony Fauci stated during his teleconference with Mr. Nanshan Zhong on the 2nd of March 2021, "the rollover of vaccine will take 2-3 years before the world population can get herd immunity. This is because the vaccines may have some limitations with mutations, other new viruses, lack of global coordination etc.
Mr. Zhong added that it is hard to predict what is going to happen after 12 months as there are still lots of uncertainties, he believes it is needed to consistent monitoring is needed and that there needs to be a balance between the risks and the costs. It is more important than ever to continue to develop new drugs, new antibodies, new remedies, and more powerful vaccines.
About UPcare Group
UPCare Group Pty Ltd global biopharmaceutical company and a world leader in the development of pharmaceutical and medical products based on natural botanic combinations called UPplus® with programs for COVID-19. UPcare has developed UPplus KBD Spray™ (an antiviral oral spray for COVID-19) and UPplus A Capsules™, (an antiviral capsule) for COVID-19, which are complementary to vaccines and other preventative measures such as distancing and PPE. Both UPplus® products are approved by both Australia and USA government authorities and registered for free sale.
As a leading company in the botanic based drug delivery, UPcare’s proprietary drug delivery platform Apex Biotech Research, which has been collaborating with the prestigious Monash Univeristy is being used to screening compounds, improve pharmaceuticals, to reduce toxicities and enhance their performance.
About UPplus KBD Spray™

UPPlus KBD Spray ™is an essential complementary medicine with two powerful compounds UP-U and UP-P and designed to assist everyone against respiratory infections. As a broad spectrum spray, it an easy to use antiviral oral spray, which can be stored at room temperature and does not require refrigeration. UPPLUS KBD Spray™ helps:
Enhance/promote general health and wellbeing
Enhance/improve/promote immune defence/immunity
Helps reduce occurrence of symptoms of upper respiratory tract infections
Relieve dry throat
Relieve itchy throat
UPplus KBD Spray™ contains UP-U and UP-P (Reynoutria japonica extract and Eriobotrya japonica extract)where UP-U has been shown in laboratory studies to inactivate a broad spectrum of respiratory viruses in safe dosage, including >80% of coronavirus SARS-CoV-2 (the virus that causes COVID-19). UP-U has been shown to be virucidal, inactivating >82.2% of SARS-CoV-2 within 48 hours.
Scientific research also shows that UP-U and UP-P to have both passed toxcity study, and already in clinical trial stage. The upper respiratory site including throat is the primary site where SARS-CoV-2 (COVID-19) becomes established for around 4 days, before spreading to the lungs. The virus is irreversibly blocked and inhibited from infecting mucosal cells, thereby providing a physical barrier to respiratory viruses in the throat.
UPplus KBD Spray formulation is patented by Apex Biotech under UPcare Group. UPplus KBD Spray™ could provide additional support, in addition to conventional PPE and vaccine-based prevention strategies, for frontline doctors, nurses and other essential workers and in crowded and high-risk environments, such as public transport and aged care. It also complements Vaccine to boost more immunity and reduce upper respiratory tract infections.
UPplus KBD Spray™ is registered for sale in Australia and USA (Both Approved), and is also available for sale online now via www.upcare.tech
About UPplus A Capsules™

UPplus A Capsules™ are powerful complementary medicines combining three natural compunds of UPplus-A, UPplus-U and UPplus-P to assist people against respiratory infections. UPPLUS A Capsules™ help:
Enhance/improve/promote immune defence/immunity
Decrease/reduce/relieve mild bronchial irritation
Relieve symptoms of mild upper respiratory tract infections
Decrease/reduce/relieve symptoms of common cold
Decrease/reduce/relieve cough Maintain/support lung health
Relieve symptoms of sore throat/pharyngitis
UPplus A Capsules™ contains UP-A, UP-U and UP-P where the UP-A has been shown in laboratory studies to inactivate a broad spectrum of respiratory viruses, including >99.7% of coronavirus SARS-CoV-2 (the virus that causes COVID-19). Three compounds combination also has been shown similar level of antivirus capability, inactivating >99.7% of SARS-CoV-2 within 48 hours within safe dosage.
UPplus A Capsules™ could provide stronger additional line of defence in addition to conventional PPE and vaccines for frontline workers and people in crisis environment such as public transport and aged care. UPplus formulation is patented by Apex Biotech under UPcare Group and a specific PCT patent application has been filed for its use in capsules.
UPplus A Capsule™ is registered for sale in Australia and USA, and is available for sale online, www.upcare.tech
Comments